Company news
Summit Therapeutics Inc. news in 2021
Summit Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
December 19, 2021
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021
November 14, 2021
Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte Gayko
November 2, 2021
Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors
October 7, 2021
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021
September 29, 2021
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021
August 10, 2021
Summit Therapeutics Provides Update on Ri-CoDIFy Trials
August 10, 2021
Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole
July 11, 2021
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
June 30, 2021
Summit Therapeutics set to join Russell 3000® Index
June 7, 2021
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
May 17, 2021
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
May 16, 2021
Summit Therapeutics Announces Closing of $75 Million Rights Offering
May 11, 2021
Summit Therapeutics Publishes Scientific Updates to Corporate Website
May 5, 2021
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
May 4, 2021
Summit Therapeutics Announces Commencement of Rights Offering
April 20, 2021
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
March 16, 2021